• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Calliditas Therapeutics

Less than 1K followers
All
Webcasts
Press releases
ShowingAll content types

Regulatory press release30.09.2024 klo 15.30

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics
Regulatory press release16.09.2024 klo 16.30

Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

Calliditas Therapeutics
Regulatory press release03.09.2024 klo 13.15

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

Calliditas Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release03.09.2024 klo 13.00

Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics
Press release15.08.2024 klo 12.45

Redeye: Calliditas Update - The Final Countdown

Calliditas Therapeutics
Calliditas Therapeutics, Audiocast with teleconference, Q2'24
Webcast13.08.2024 klo 15.30

Calliditas Therapeutics, Audiocast with teleconference, Q2'24

Calliditas Therapeutics
Regulatory press release13.08.2024 klo 08.00

Calliditas Therapeutics: Calliditas Interim Report January to June 2024

Calliditas Therapeutics
Press release05.08.2024 klo 08.00

Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024

Calliditas Therapeutics
Regulatory press release31.07.2024 klo 15.00

Number of shares and votes in Calliditas Therapeutics

Calliditas Therapeutics
Press release26.07.2024 klo 18.00

Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

Calliditas Therapeutics
Regulatory press release26.07.2024 klo 09.00

Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

Calliditas Therapeutics
Press release04.07.2024 klo 09.30

Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan

Calliditas Therapeutics
Press release18.06.2024 klo 13.15

Calliditas Therapeutics: Calliditas provides setanaxib patent update

Calliditas Therapeutics
Regulatory press release17.06.2024 klo 18.30

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics
Regulatory press release30.05.2024 klo 21.00

Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy

Calliditas Therapeutics
Calliditas Therapeutics R&D Day, 2024
Webcast30.05.2024 klo 16.00

Calliditas Therapeutics R&D Day, 2024

Calliditas Therapeutics
Press release28.05.2024 klo 15.00

Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress

Calliditas Therapeutics
Regulatory press release28.05.2024 klo 09.30

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

Calliditas Therapeutics
Press release24.05.2024 klo 08.11

Redeye: Calliditas Q1 - Powerful launch momentum

Calliditas Therapeutics
Calliditas Therapeutics, Audiocast with teleconference, Q1'24
Webcast23.05.2024 klo 15.30

Calliditas Therapeutics, Audiocast with teleconference, Q1'24

Calliditas Therapeutics